BioXcel Therapeutics Inc. (NASDAQ:BTAI)’s traded shares stood at 2.91 million during the last session, with the company’s beta value hitting 1.23. At the close of trading, the stock’s price was $19.42, to imply a decrease of -0.10% or -$0.02 in intraday trading. The BTAI share’s 52-week high remains $34.12, putting it -75.7% down since that peak but still an impressive 54.69% since price per share fell to its 52-week low of $8.80. The company has a valuation of $647.07M, with an average of 0.62 million shares in intraday trading volume over the past 10 days and average of 413.44K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for BioXcel Therapeutics Inc. (BTAI), translating to a mean rating of 1.70. Of 9 analyst(s) looking at the stock, 0 analyst(s) give BTAI a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.44.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
BioXcel Therapeutics Inc. (NASDAQ:BTAI) trade information
After registering a -0.10% downside in the last session, BioXcel Therapeutics Inc. (BTAI) has traded red over the past five days. The stock hit a weekly high of 22.53 this Friday, 03/17/23, dropping -0.10% in its intraday price action. The 5-day price performance for the stock is -6.00%, and -40.56% over 30 days. With these gigs, the year-to-date price performance is -9.59%. Short interest in BioXcel Therapeutics Inc. (NASDAQ:BTAI) saw shorts transact 2.45 million shares and set a 6.72 days time to cover.
Analysts on Wall Street suggest a consensus price target of $53.70, implying an increase of 63.84% to the stock’s current value. The extremes give us $22.00 and $79.00 for target low and target high price respectively. As such, BTAI has been trading -306.8% off suggested target high and -13.29% from its likely low.
BioXcel Therapeutics Inc. (BTAI) estimates and forecasts
Looking at statistics comparing BioXcel Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. BioXcel Therapeutics Inc. (BTAI) shares are 46.35% up over the last 6 months, with its year-to-date growth rate lower than industry average at 2.70% against 9.60%. Revenue is forecast to shrink -54.80% this quarter before falling -44.60% for the next one.
Revenue forecast for the current quarter as set by 9 analysts is $1.32 million. Meanwhile, for the quarter ending Mar 2023, a total of 4 analyst(s) estimate revenue growth to $2 million.
BioXcel Therapeutics Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. BioXcel Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
BioXcel Therapeutics Inc. (NASDAQ:BTAI)’s Major holders
BioXcel Therapeutics Inc. insiders hold 32.22% of total outstanding shares, with institutional holders owning 53.57% of the shares at 79.03% float percentage. In total, 53.57% institutions holds shares in the company, led by FMR, LLC. As of Sep 29, 2022, the company held over 4.2 million shares (or 14.98% of shares), all amounting to roughly $49.62 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 1.46 million shares, or about 5.22% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $17.3 million.
We also have Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the BioXcel Therapeutics Inc. (BTAI) shares. Going by data provided on Nov 29, 2022, Fidelity Growth Company Fund holds roughly 1.35 million shares. This is just over 4.81% of the total shares, with a market valuation of $22.33 million. Data from the same date shows that the other fund manager holds a little less at 0.65 million, or 2.30% of the shares, all valued at about 7.63 million.